Keith Hall has over 30 years of biopharmaceutical experience including product development, manufacturing, process development, assay development, quality and CMC regulatory. He joined Wacker Biotech US in February 2021 as Chief of Operations following the acquisition of Genopis Inc., where he served as Chief Operating Office from August 2018. Prior to his tenure at Genopis he worked at Vical for 15 years in various roles of increasing responsibly, the last being Vice President of Operations. From 2000 to 2003 he served as Director of Manufacturing for Agennix in Houston, TX where he oversaw drug substance and product manufacture, and the design, construction and commissioning of a recombinant human lactoferrin bulk drug substance manufacturing facility in Italy. From 1994 to 2000 he served as Senior Manager, Quality Control and Analytical Development for Valentis/GeneMedicine in The Woodlands, TX. Prior to 1994, Mr. Hall served in various development and manufacturing positions of increasing responsibilities at Hybritech and Amgen. He earned a master’s degree in business administration from the C.T. Bauer College of Business at the University of Houston, and a bachelor’s degree in microbiology from the University of California at Santa Barbara.
